Anika Therapeutics, Inc. ANIK
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -6.18% | 10.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.18% | 10.12% | |||
| Cost of Revenue | 3.44% | 7.07% | |||
| Gross Profit | -11.33% | 11.83% | |||
| SG&A Expenses | 13.27% | -37.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.95% | -13.81% | |||
| Operating Income | -115.70% | 195.51% | |||
| Income Before Tax | -109.53% | 170.11% | |||
| Income Tax Expenses | -115.49% | -69.79% | |||
| Earnings from Continuing Operations | -109.40% | 165.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.40% | 165.45% | |||
| EBIT | -115.70% | 195.51% | |||
| EBITDA | -83.67% | 309.74% | |||
| EPS Basic | -109.35% | 166.42% | |||
| Normalized Basic EPS | -104.67% | 230.32% | |||
| EPS Diluted | -109.67% | 164.22% | |||
| Normalized Diluted EPS | -104.81% | 226.64% | |||
| Average Basic Shares Outstanding | 0.44% | -1.49% | |||
| Average Diluted Shares Outstanding | -2.40% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||